Topiramate: A new antiepileptic drug

Annals of Pharmacotherapy

Volumn 31, Issue 10, 1997, Pages 1164-1173

  Privitera, Michael D ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Epilepsy; Topiramate

Indexed keywords

TOPIRAMATE;

ANTICONVULSANT THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EPILEPSY; FOCAL EPILEPSY; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030931470     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703101010     Document Type: Review

References (66)

1. Swinyard EA, Woodhead JH, White HS, Franklin MR. General principles: experimental selection, quantification and evaluation of anticonvulsants. In: Levy R, Mattson RM, Meldrum B, Penry JK, Dreifuss FE, eds. Antiepileptic drugs. 3rd ed. New York: Raven Press, 1989:85-102.
2. Shank RP, Vaught JL, Raffa RB, Maryanoff BE. Investigation of the mechanism of topiramate's anticonvulsant activity. Epilepsia 1991;32:7-8.
3. Shank RP, Gardocki JF, Vaught JL, Davis CB, Schupsky JJ, Raffa RB, et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994;35:450-60.
4. White HS, Woodhead JH, Wolf HH. Effect of topiramate (TPM) on pentylenetetrazol (PTZ) seizure threshold (abstract). Epilepsia 1996;37 (suppl 5):26.
5. Nakamura J, Tanura S, Kanda T, Ishii A, Ishihara K, Serikawa T, et al. Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice. Eur J Pharmacol 1994;254:83-9.
6. Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 1995;36(suppl 2):S2-12.
7. Coulter DA, Sombati S, DeLorenzo RJ. Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons (abstract). Epilepsia 1993;34(suppl 2):123.
8. 2+-induced seizure discharged in cultured hippocampal neurons (abstract). Epilepsia 1995;36(suppl 4):38.
9. Brown SD, Wolf HH, Swinyard EA, Twyman RE, White HS. The novel anticonvulsant topiramate enhances GABA-mediated chloride flux (abstract). Epilepsia 1993;34(suppl 2):122.
10. White HS, Brown SD, Wolf HH, Twyman RE. The anticonvulsant topiramate potentiates GABA-evoked chloride currents in mouse cortical neurons (abstract). Epilepsia 1994;35(suppl 8):67.
11. White HS, Brown D, Skeen GA, Wolf HH, Twyman RE. The anticonvulsant topiramate displays a unique ability to potentiate GABA-evoked chloride currents (abstract). Epilepsia 1995:36(suppl 3):S39-40.
12. White HS, Brown SD, Skeen GA, Twyman RE. The investigational anticonvulsant topiramate potentiates GABA-evoked currents in mouse cortical neurons (abstract). Epilepsia 1995;36(suppl 4):34.
13. Gordey M, Delorey TM, Olsen RW. Topiramate modulates GABA receptor responses in Xenopus oocytes expressing several recombinant receptor subunit combinations (abstract). Epilepsia 1995;36(suppl 4):48.
14. Coulter DA, Sombati S, DeLorenzo RJ. Topiramate effects on excitatory amino acid-mediated responses in cultured hippocampal neurons: selective blockade of kainate currents (abstract). Epilepsia 1995;36(suppl 3):S40.
15. Vaught JL, Maryanoff BE, Shank RP. The pharmacological profile of topiramate: a structurally novel, clinically effective anticonvulsant (abstract). Epilepsia 1991;32(suppl 3):19.
16. Ben-Menachem E. Potential antiepileptic drugs: topiramate. In: Levy RH, Mattson RM, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:1063-70.
17. Bourgeois BFD. Important pharmacokinetic properties of antiepileptic drugs. Epilepsia 1995;36(suppl 5):S1-7.
18. Easterling DE, Zakszewski T, Moyer MD, Margul BL, Marriott TB, Nayak RK. Plasma pharmacokinetics of topiramate, a new anticonvulsant in humans (abstract). Epilepsia 1988;29:662.
19. Data on file. RW Johnson Pharmaceutical Research Institute, Raritan, NJ.
20. Gisclon LG, Curtin CR, Kramer LD. The steady-state (SS) pharmacokinetics (PK) of phenytoin (Dilantin) and topiramate (Topamax) in epileptic patients on monotherapy and during combination therapy (abstract). Epilepsia 1994;35(suppl 8):54.
21. Doose DR, Walker SA, Sachdeo R, Kramer LD, Nayak RK. Steady-state pharmacokinetics of Tegretol (carbamazepine) and Topamax (topiramate) in patients with epilepsy on monotherapy, and during combination therapy (abstract). Epilepsia 1994;35(suppl 8):54.
22. Gisclon LG, Riffits JM, Sica DA, Gehr T, Ruddley J. The pharmacokinetics (PK) of topiramate (T) in subjects with renal impairment (RI) as compared to matched subjects with normal renal function (NRF) (abstract). Pharm Res 1993;10(suppl 10):S397.
23. Doose DR, Walker SA, Venkataramanan R, Rabinovitz M, Lever J. Topiramate pharmacokinetics in subjects with liver impairment (abstract). Pharm Res 1994;11(suppl 10):S446.
24. Faught E, Wilder BJ, Ramsay RE, Reife RA, Kramer LD, Pledger GW, et al. Topiramate placebo-controlled dose-ranging trial in refractory epilepsy using 200-, 400-and 600-mg daily dosages. Neurology 1996; 46:1684-90.
25. Privitera M, Fincham R, Penry J, Reife R, Kramer L, Pledger G, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-and 1000-mg daily dosages. Neurology 1996; 46:1678-83.
26. Martinez-Lage J, Ben-Menachem E, Shorvon SD, Weber M. Double-blind, placebo-controlled trial of 400 mg/day topiramate as add-on therapy in patients with refractory partial epilepsy (abstract). Epilepsia 1995; 36(suppl 3):S149-50.
27. Tassinari CA, Michelucci R, Chauvel P, Chodkiewicz J, Shorvon S, Henriksen O, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37:763-8.
28. Ben-Menachem E, Henriksen O, Dam M, Mikkelsen M, Schmidt D, Reid S, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37: 539-43.
29. Conover WJ, Iman RL. Rank transformation as a bridge between parametric and nonparametric statistics. Am Statistician 1981;35:124-33.
30. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley and Sons, 1981.
31. Lehman EL. Nonparametrics: statistical methods based on ranks. San Francisco: Holden Day, 1975.
32. Pledger G, Reife RA, Lim P, Karim P. Overview of topiramate efficacy from adjunctive therapy trials (abstract). Epilepsia 1995;36(suppl 3): S150.
33. Pledger GW, Schmidt D. Evaluation of antiepileptic drug efficacy: a review of clinical trial design. Drugs 1994;48:498-509.
34. Sachdeo SK, Sachdeo RC, Reife RA, Lim P, Pledger G. Topiramate: double-blind trial as monotherapy (abstract). Epilepsia 1995;36(suppl 4):33.
35. French JA, Bourgeois BFD, Dreifuss FE, Glauser TA, Ritter FJ, Reife RA, et al. An open-label multicenter study of topiramate in patients with the Lennox-Gastaut syndrome (abstract). Neurology 1995;45(suppl 4):A250.
36. Espe-Lillo J, Ritter FJ, Frost MD, Spiegel RH, Reife RA. Topiramate in childhood epilepsy: titration, adverse events, and efficacy in multiple seizure types (abstract). Epilepsia 1995;36(suppl 4):56.
37. Biton V, Reife R, Kamin M, Bobrosky K. Topiramate (Topamax) as add-on therapy for patients with primary generalized epilepsy (abstract). Neurology 1996;43:A176.
38. Privitera M. Long-term efficacy and safety of topiramate (abstract). Epilepsia 1995;36(suppl 3):S152.
39. Rosenfeld WE, Sachdeo RC. Topiramate can be a successful monotherapy drug (abstract). Epilepsia 1995;36(suppl 4):56.
40. Ben-Menachem E. Long-term follow-up of patients treated with topiramate for partial seizures (abstract). Epilepsia 1995;36(suppl 3):S152.
41. Cowell PG, Coles HJ, Crawford PM. Topiramate as adjunctive therapy in patients with refractory epilepsy: a report of a long-term, open-label study (abstract). Epilepsia 1995;36(suppl 3):S152.
42. Engelskjon T, Johannessen SI, Kloster R, Nakken KO, Lossius R, Henriksen O. Long-term effect of topiramate in refractory partial epilepsy (abstract). Epilepsia 1993;34(suppl 2):123.
43. Mikkelsen M, Ostergaard L, Dam M. Topiramate as long-term treatment in refractory partial epilepsy (abstract). Epilepsia 1993;35(suppl 2):123.
44. Michelucci R, Passarelli D, Tassinari CA. Topiramate in the treatment of refractory partial epilepsy: a double-blind study with long-term follow-up (abstract). Epilepsia 1995;36(suppl 3):S150.
45. Tartara A, Sartori I, Manni R, Galimberti CA, DiFazio M, Perucca E. Add-on trial of topiramate in refractory epilepsy (abstract). Epilepsia 1995;36(suppl 3):S150.
46. Fincham RW, Schottelius D. Long-term therapy with topiramate in partial seizures (abstract). Epilepsia 1995;36(suppl 4):56.
47. Package insert. Topamax (topiramate). Raritan, NJ: Ortho McNeil Pharmaceutical, December 1996.
48. Reife RA, Pledger G, Doose D, Lim P, Ward C. Topiramate: PK/PD analyses (abstract). Epilepsia 1995;35(suppl 3):S152.
49. Reife RA, Lim P, Pledger G. Topiramate: side effect profile in double-blind studies (abstract). Epilepsia 1995;36(suppl 4):34.
50. Wasserstein AG, Rak I, Reife RA. Nephrolithiasis during treatment with topiramate (abstract). Epilepsia 1995;36(suppl 3):S153.
51. Liao S, Rosenfeld WE, Palmer M, Schaefer P, Pace K, Nayak RK. Steady-state pharmacokinetics of topiramate and valproic acid in patients with epilepsy on monotherapy and during combination therapy (abstract). Epilepsia 1994;35(suppl 8):117.
52. Doose DR, Walker SA, Pledger G, Lim P, Reife RA. Evaluation of phenobarbital and primidone/phenobarbital (primidone's active metabolite) plasma concentrations during administration of add-on topiramate therapy in five multicenter, double-blind, placebo-controlled trials in outpatients with partial seizures (abstract). Epilepsia 1995;36(suppl 3):S158.
53. Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 1997;38: 317-23.
54. Liao S, Palmer M. Digoxin and topiramate drug interaction study in male volunteers (abstract). Pharm Res 1993;10(suppl):S405.
55. Levy RH, Bishop F, Streeter AJ, Trager WF, Kunze KL, Thummel KT, et al. Explanation and prediction of drug interactions with topiramate using a CYP450 inhibition spectrum (abstract). Epilepsia 1995;36(suppl 4):47.
56. Rosenfeld WE, Doose DR, Walker SA, Schaefer P, Reife RA. Steady-state pharmacokinetics of topiramate as adjunctive therapy in pediatric subjects with epilepsy (abstract). Epilepsia 1995;36(suppl 3):S158.
57. Thanedar S, Rosenfeld WE. Topiramate well tolerated by pediatric patients (abstract). Epilepsia 1995;36(suppl 4):34.
58. Mattson RH, Cramer JA, Collins JF, and the Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992;327:765-71.
59. Heller AJ, Chesterman P, Elwes RDC, Crawford P, Chadwick D, Johnson AL, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995;58:44-50.
60. Anhut H, Ashman P, Feuerstein TJ, Sauermann W, Saunders M, Schmidt B, et al. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. Epilepsia 1994;35:795-801.
61. US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology 1993;43:2292-8.
62. Matsuo F, Bergen D, Faught E, Messenheimer JA, Dren AT, Rudd GD, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993;43:2284-91.
63. Steiner TJ, Yuen AWC. Comparison of lamotrigine and phenytoin monotherapy in newly diagnosed epilepsy (abstract). Epilepsia 1994;35 (suppl 8):31.
64. Brodic MJ, Richens A, Yuen AWC, for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345: 476-9.
65. Cockerell OC, Hart YM, Sander JWAS, Shorvon SD. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Res 1994;18:249-60.
66. Begley CE, Annegers JF, Lairson DR, Reynolds TF, Hauser WA. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 1994;35:1230-43.